After reading your response, I have to chuckle at Kirk's view of Palifosfamide as a "rounding error".
Amrn: $14.50 was where I said I would re-enter when I sold my position on 4/18. So it is kind of stuck in my head. I agree that it may very well have been fairly valued at $17 where I sold out.
Aria: I know you were a skeptic due to Mrk's lack of pounding the table on Rida after the Succeed results. Are you looking to the follow through data (good or bad) as a potential entry?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.